Allergan PLC posted better than expected product sales for the second quarter on 6 Aug. with its blockbusters Botox (onabotulinumtoxinA) and Restasis (cyclosporine) holding up well versus competitive pressures. Yet despite the good news for AbbVie Inc., which is paying $63bn for Allergan primarily for its Botox-fueled revenue stream, the companies still can't shake external concerns that the top-selling wrinkle reducer's sales won't hold up over time.
Investors have good reason to worry, since Botox is facing new competition in its two biggest categories – medical aesthetics...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?